Arbutus Biopharma (NASDAQ:ABUS) just reported results for the first quarter of 2024.
- Arbutus Biopharma reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -11 cents.
- The company reported revenue of $1.53 million.
- This was 28.74% worse than the analyst estimate for revenue of $2.15 million.